March 19, 2018 3:00 PM ET


Company Overview of Oxford BioTherapeutics Ltd

Company Overview

Oxford BioTherapeutics Ltd, a biotechnology company, develops antibody-drug conjugates to treat cancer. It provides OGAP, a target discovery system that provides a range of validated and novel antigen targets identified from a range of cancer types; and develops antibody-based treatments for acute myeloid leukemia and breast, ovarian, and lung cancers. Oxford BioTherapeutics Ltd was formerly known as Oxford Genome Sciences (UK) Limited and changed its name to Oxford BioTherapeutics Ltd in December 2008. The company was incorporated in 2003 and is based in Oxon, United Kingdom with a location in San Jose, California.

94A Innovation Drive

Milton Park


Oxon,  OX14 4RZ

United Kingdom

Founded in 2003


44 1235 861 770


44 1235 861 771

Key Executives for Oxford BioTherapeutics Ltd

Founder, Chief Executive Officer & Director
Senior Director of Finance
UK Site Head and Scientific Director
Senior Vice President of Protein Sciences
Senior Vice President of Non-Clinical Development
Compensation as of Fiscal Year 2017.

Oxford BioTherapeutics Ltd Key Developments

Oxford BioTherapeutics Appoints Abderrahim Fandi as Chief Medical Officer

Oxford BioTherapeutics announced the appointment of Abderrahim (Rahim) Fandi, M.D., Ph.D. to the newly created position of Chief Medical Officer (CMO). Dr. Fandi will oversee the development of OBT's immune-oncology portfolio. Prior to joining OBT, Dr. Fandi was Executive Director - site head at Celgene, where he led the development of several oncology compounds and participated in successful regulatory interactions, including with the FDA.

Oxford Biotherapeutics Presents at BIO One-on-One Partnering™, Jan-07-2018

Oxford Biotherapeutics Presents at BIO One-on-One Partnering™, Jan-07-2018 . Venue: San Francisco, California, United States.

Oxford BioTherapeutics Appoints John McHutchison to its Board of Directors

Oxford BioTherapeutics has appointed Dr. John McHutchison, Executive Vice President, Clinical Research, Gilead Sciences to its Board of Directors. Dr. McHutchison brings almost 20 years of clinical and drug development experience to the Board, most recently in his tenure at Gilead. He is responsible for Gilead's development programs in liver diseases, haematology and oncology, and inflammatory and respiratory diseases, having previously served as Senior Vice President, Liver Disease Therapeutics. In his six years at Gilead, he has led the organisation in the successful filing of five NDAs and numerous supplemental label updates across multiple therapeutic areas, including the successful curative HCV regimens. Dr. McHutchison also brings to the Board a wealth of experience from prior academic roles at Duke University Medical Centre, North Carolina, USA; Scripps Clinic, San Diego, USA; and the University of Southern California USA.

Similar Private Companies By Industry

Company Name Region
Abcellute Ltd. Europe
Abcodia Ltd. Europe
Abeterno Ltd. Europe
Abgentis Limited Europe
Achilles Therapeutics Ltd. Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Oxford BioTherapeutics Ltd, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at